Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer (Q36539266)

14 August 2017

title

Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer (English)

1 reference

14 August 2017

1 reference

3

Aimery de Gramont

0 references

Jaffer Ajani

7

object named as

Jaffer A Ajani

1 reference

14 August 2017

Howard S Hochster

1

1 reference

14 August 2017

Daniel G Haller

2

1 reference

14 August 2017

Jordan D Berlin

4

1 reference

14 August 2017

Philip A Philip

5

1 reference

14 August 2017

Malcolm J Moore

6

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

14 August 2017

number of pages

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

14 August 2017

volume

107

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

676-685

1 reference

14 August 2017

cites work

Cancer statistics, 2004

1 reference

7 January 2021

Systemic treatment of pancreatic cancer

1 reference

7 January 2021

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

7 January 2021

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study

1 reference

7 January 2021

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

1 reference

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

7 January 2021

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

7 January 2021

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

7 January 2021

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

7 January 2021

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

7 January 2021

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

7 January 2021

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

7 January 2021

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

7 January 2021

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

7 January 2021

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

7 January 2021

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

1 reference

7 January 2021

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

1 reference

7 January 2021

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

7 January 2021

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

1 reference

7 January 2021

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial

1 reference

7 January 2021

Complications of malignancy: case 3. Chronic lymphocytic leukemia presenting with panhypopituitarism

1 reference

7 January 2021

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

7 January 2021

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

1 reference

7 January 2021

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

1 reference

7 January 2021

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).

1 reference

7 January 2021

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

1 reference

7 January 2021

Identifiers

DOI

10.1002/CNCR.22036

1 reference

14 August 2017

1 reference